HS-10504 clinical trials
Also written HS-10504.
How each study uses HS-10504 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HS-10504 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HS-10504
- 5
Studies by the year they started
6 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test HS-10504.
- Dec 2026A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)Phase 1 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Mar 2027A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504Phase 1 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Sep 2027A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.Phase 1 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses HS-10504 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLCRecruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07754123Written as HS-10504
- A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.Not yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07836504Written as HS-10504
- A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)RecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06461156Written as HS-10504
- A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504Not yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07770217Written as HS-10504
- A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504Not yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07764692Written as HS-10504
- A Mass Balance Study of [14C]HS-10504Not yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07764705Written as [¹⁴C]HS-10504